Urogen's Potential First Non-Surgical Therapy for LG-IR-NMIBC Posts Promising Phase 3 Trial Data

-- In ATLAS, UGN-102 Demonstrated Superiority to TURBT with a 55% Reduction of Risk for Recurrence, Progression or Death in Patients who Received UGN-102 --ENVISION Showed a Complete Response Rate of 79.2% at 3-Months --
-- Side Effect Profile in ATLAS and ENVISION Consistent with Previous Clinical Trials of UGN-102 --